Precigen Inc (PGEN) Stock Price, Quote & News

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine an...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 556 9900

Website: precigen.com

Address:

20374 Seneca Meadows Parkway, Germantown, United States

bavariaron Dec. 13 at 11:19 AM

** 2025 M&A Review & 2026 Outlook ** Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify “With less than a month of 2025 to go, data already shows a significant jump in deal value compared to 2024. What acted as M&A fuel this year, and what could be in store in 2026?” “Overall deal value is up, but the volume’s down. That’s an indication that the deal sizes have gone up. The average deal size now is nearly at about $1.9bn-$2BN mark, which is significantly higher than full year 2024,” says EY LifeSciences global deals leader Subin Baral.“ The looming patent cliff - one of the worst-kept secrets in the pharma industry – is a central force behind the dealmaking in 2025. VKTX $IOVA $PGEN $SGMO https://finance.yahoo.com/news/biopharma-2025-m-boom-dealmaking-124407300.html

0 · Reply

M22 Dec. 13 at 1:04 AM

$PGEN worth reading -> https://people.com/teen-vocal-cords-12-procedures-exclusive-11847024

1 · Reply

forgottenchuck Dec. 12 at 8:25 PM

$PGEN just got word that the vaccine is flying off the shelfs

2 · Reply

Tapa Dec. 12 at 7:43 PM

$PGEN her comes the 3pm sell off. WTF

0 · Reply

wallstbullinfinity Dec. 12 at 7:29 PM

$PGEN Unblocking me and popping back up in the feeds is like going out your way to see my posts in fear of missing ish... what up dork... see you back at it like a crack addict. $INO can't be ignored 🧬🧬🧬🌏🌎🌍

1 · Reply

Redwood1205 Dec. 12 at 6:56 PM

$PGEN I look at the data

1 · Reply

Bordeaux17 Dec. 12 at 6:54 PM

$PGEN Rooting for INO while trashing Papzimeos is like betting on a unicorn in a race and booing the thoroughbred that already crossed the finish line. 🤡 where do you even come up with this nonsense?

0 · Reply

Pharmer23 Dec. 12 at 6:38 PM

$PGEN the swings have been wild .

1 · Reply

Redwood1205 Dec. 12 at 6:03 PM

$PGEN the unmet need is for patients with 3 or less prior year surgeries. The one or two MRD's during treatment combined with many non-responders make 2012 a joke for most not very severe RRP patients

1 · Reply

Cascas007 Dec. 12 at 3:59 PM

$PGEN INOVIO priority review. Guess? They have everything checked to get priority review except the unmet need. This is no longer valid. So what do you all think? Will they get priority status for their BLA?

2 · Reply

Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?

Nov 25, 2025, 6:51 AM EST - 18 days ago

Precigen Is Still A Buy After The Papzimeos Rally

Nov 13, 2025, 10:51 PM EST - 4 weeks ago

Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 4 weeks ago

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 4:30 PM EST - 5 weeks ago

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Nov 1, 2025, 12:33 PM EDT - 6 weeks ago

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares

Oct 13, 2025, 7:00 AM EDT - 2 months ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Sep 7, 2025, 8:23 AM EDT - 3 months ago

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

MLYS

Sep 3, 2025, 7:00 AM EDT - 3 months ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 2, 2025, 1:55 PM EDT - 3 months ago

Precigen, Inc. - Special Call

Aug 25, 2025, 8:05 AM EDT - 3 months ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Aug 22, 2025, 10:43 AM EDT - 4 months ago

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

BMNR OKE

Aug 15, 2025, 3:15 PM EDT - 4 months ago

Precigen: This Billion-Dollar Approval Is Still Undervalued

Aug 15, 2025, 9:48 AM EDT - 4 months ago

Why Is Precigen Stock Surging On Friday?

Aug 15, 2025, 7:18 AM EDT - 4 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:00 AM EDT - 4 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Jul 7, 2025, 5:58 PM EDT - 5 months ago

Precigen: August Is Pivotal For This Biotech Innovator

May 14, 2025, 4:05 PM EDT - 7 months ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Apr 16, 2025, 8:05 AM EDT - 8 months ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Mar 19, 2025, 7:47 PM EDT - 9 months ago

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 4:05 PM EDT - 9 months ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 13, 2025, 8:05 AM EDT - 9 months ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Feb 28, 2025, 8:56 AM EST - 10 months ago

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Feb 25, 2025, 8:05 AM EST - 10 months ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Jan 13, 2025, 7:00 AM EST - 11 months ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 1 year ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 7:00 AM EST - 1 year ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 27, 2024, 9:00 AM EST - 1 year ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Aug 15, 2024, 8:11 AM EDT - 1 year ago

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

GGR TITN

Aug 14, 2024, 7:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jun 3, 2024, 9:30 AM EDT - 1 year ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

May 23, 2024, 5:00 PM EDT - 1 year ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 8, 2024, 4:05 PM EDT - 1 year ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 1 year ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 19, 2024, 8:49 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 5, 2024, 4:05 PM EST - 1 year ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

bavariaron Dec. 13 at 11:19 AM

0 · Reply

M22 Dec. 13 at 1:04 AM

$PGEN worth reading -> https://people.com/teen-vocal-cords-12-procedures-exclusive-11847024

1 · Reply

forgottenchuck Dec. 12 at 8:25 PM

$PGEN just got word that the vaccine is flying off the shelfs

2 · Reply

Tapa Dec. 12 at 7:43 PM

$PGEN her comes the 3pm sell off. WTF

0 · Reply

wallstbullinfinity Dec. 12 at 7:29 PM

1 · Reply

Redwood1205 Dec. 12 at 6:56 PM

$PGEN I look at the data

1 · Reply

Bordeaux17 Dec. 12 at 6:54 PM

0 · Reply

Pharmer23 Dec. 12 at 6:38 PM

$PGEN the swings have been wild .

1 · Reply

Redwood1205 Dec. 12 at 6:03 PM

1 · Reply

Cascas007 Dec. 12 at 3:59 PM

2 · Reply

Golfer109 Dec. 11 at 4:45 PM

$PGEN sometimes during the holidays magic does come in our stock really needs that magic so for all of us think Magic and maybe it'll happen

0 · Reply

blue_horseshoe_9P Dec. 11 at 3:50 PM

$PGEN I’m not going to fall for this spike and get excited. It never holds any gains. Frustrating.

1 · Reply

betonthenews Dec. 10 at 7:59 PM

$PGEN @Tlinz50 The whole sale discount is 15% to low 20%, the list price is 460k, use 23% discount rate, net 460K x 77% = $354K/patient, let's assume your number 300 patients on list waiting signed up for treatments, and if 25% of 300 patients treated in Q4, that is 25%X300X$354K=$26.5M Q4 revenue, if PGEN report initial Q4 $26M revenue before JPM conference, street may be very happy to see and upgrade 2026 estimates to $200+M, IMO.

3 · Reply

Sw1ngb0t Dec. 10 at 7:06 PM

$PGEN it's almost time to pamp

0 · Reply

betonthenews Dec. 10 at 4:55 PM

$PGEN Presentation at California East room 7:30 AM https://x.com/bradloncar/status/1998532458933833899/photo/4 PGEN needs solid Q4 numbers to add the "MEAT" to the presentation, otherwise, it is all empty talk, IMO.

1 · Reply

betonthenews Dec. 10 at 3:57 PM

$PGEN is going to present at JPM health conference on Jan 15, 2026, Thursday 7:30 AM, good chance PGEN is going to PR initial Q4 numbers before the presentation, IMO.

1 · Reply

dsup Dec. 10 at 3:18 AM

$PGEN the streets estimate for revenue q4 at this point in time is 8 million. if they can crush that which i believe is possible… 😳

1 · Reply

SimpleWinningSetups Dec. 9 at 9:22 PM

Hedge Alert Live - Protect Your Portfolio Contract: $PGEN $3.50 Put · DEC 19, 2025 Exp Entry Price: $0.17 - $0.30 Exit Price Target: $0.30 Profit Margin: +79% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Estimize Dec. 9 at 9:00 PM

Wall St is expecting -0.08 EPS for $PGEN Q4 [Reporting 03/09 AMC] http://www.estimize.com/intro/pgen?chart=historical&metric_name=eps&utm_c

0 · Reply

M22 Dec. 9 at 4:39 PM

$PGEN us older pigeons will get this

0 · Reply

M22 Dec. 9 at 2:55 PM

$PGEN interesting point of view and Grok naming Precigen as one of 3 players in this field 🧐 https://x.com/nishant_bliss/status/1997316542825107780?s=46&t=x7fYsMSp5ZaR-NlwJbyy1A

1 · Reply

longshort777 Dec. 9 at 3:51 AM

$PGEN

1 · Reply

Market Cap	1.28B
Revenue (ttm)	3.93M
Net Income (ttm)	-126.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,212.21%
Debt to Equity Ratio	2.22

Volume	3,729,600
Avg Vol	4,366,568
Day's Range	N/A - N/A
Shares Out	353.83M
Stochastic %K	63%
Beta	1.16
Analysts	Sell
Price Target	$8.50